<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1870-7203</journal-id>
<journal-title><![CDATA[Acta médica Grupo Ángeles]]></journal-title>
<abbrev-journal-title><![CDATA[Acta méd. Grupo Ángeles]]></abbrev-journal-title>
<issn>1870-7203</issn>
<publisher>
<publisher-name><![CDATA[Grupo Ángeles, Servicios de Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1870-72032020000200177</article-id>
<article-id pub-id-type="doi">10.35366/93892</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Síndrome de lisis tumoral]]></article-title>
<article-title xml:lang="en"><![CDATA[Tumor lysis syndrome]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ochoa Salmorán]]></surname>
<given-names><![CDATA[Humberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Espinosa Sevilla]]></surname>
<given-names><![CDATA[Azucena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hurtado Monroy]]></surname>
<given-names><![CDATA[Rafael]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Ángeles Pedregal Servicio de Urgencias ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Ángeles Pedregal Servicio de Urgencias ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Ángeles Pedregal Departamento de Hematología ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<volume>18</volume>
<numero>2</numero>
<fpage>177</fpage>
<lpage>184</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1870-72032020000200177&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1870-72032020000200177&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1870-72032020000200177&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: El síndrome de lisis tumoral (SLT) es una complicación grave que se caracteriza por una elevada morbimortalidad y es secundaria a la liberación de componentes celulares a la circulación posterior a la lisis masiva de células malignas. Se produce desequilibrio hidroelectrolítico que puede desencadenar lesión renal aguda, arritmias y crisis convulsivas. Puede ocurrir en el primer ciclo de quimioterapia, o durante el tratamiento. EL SLT se asocia en la mayoría de los casos con quimioterapia citotóxica, aunque también se ha descrito con el uso terapéutico de anticuerpos monoclonales. Existen dos tipos: el SLT como síndrome clínico o sólo con cambios de laboratorio. El SLT de laboratorio es más común y se define por aparición en 24 horas de dos o más alteraciones en electrolitos o ácido úrico. Para su diagnóstico se emplean los criterios de Cairo-Bishop y de Howard. Las medidas para prevenirlo incluyen monitoreo de laboratorio, uricosúricos y adecuada hidratación. La vigilancia con laboratorio se debe seguir durante el periodo de alto riesgo. La hidratación adecuada es lo principal para promover la excreción de ácido úrico y fosfato. Los hipouricemiantes como el alopurinol o agentes más nuevos como el febuxostat pueden ser efectivos. En años recientes se informa que el SLT es más frecuente con algunos de los nuevos agentes de tratamiento de la leucemia linfocítica crónica.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: Tumor lysis syndrome (TLS) is a life-threatening complication secondary to the release to the blood of cellular components following the massive lysis of malignant cells. It can trigger acute kidney injury, arrhythmias and seizures. It usually occurs in the first cycle of chemotherapy, or throughout the treatment. It is associated in most cases with cytotoxic chemotherapy, but also by the use of therapeutic anti-CD20 monoclonal antibodies. There are two types: TLS manifested as a clinical syndrome or with laboratory changes. The TLS laboratory is more common, and it is defined by the appearance in 24 hours of two or more abnormalities in electrolytes or uric acid. For its diagnosis, the Cairo-Bishop and Howard criteria are used. The measures to prevent it include monitoring of laboratories, hypouricemiantes and adequate hydration. This follow-up with laboratories should be followed during the high-risk period. Adequate hydration is the most important measure, because it promotes the excretion of uric acid and phosphate. Hypouricemic agents such as allopurinol or newer agents such as febuxostat can be effective. The TLS has been observed frequently, although not severely, with some of the new treatment agents of chronic lymphocytic leukemia.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Lisis]]></kwd>
<kwd lng="es"><![CDATA[tumoral]]></kwd>
<kwd lng="es"><![CDATA[quimioterapia]]></kwd>
<kwd lng="en"><![CDATA[Lysis]]></kwd>
<kwd lng="en"><![CDATA[tumoral]]></kwd>
<kwd lng="en"><![CDATA[chemotherapy]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheson]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
<name>
<surname><![CDATA[Heitner Enschede]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cerri]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Desai]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Potluri]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lamanna]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumor lysis syndrome in chronic lymphocytic leukemia with novel targeted agents]]></article-title>
<source><![CDATA[Oncologist]]></source>
<year>2017</year>
<volume>22</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1283-91</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klemencic]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Perkins]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and management of oncologic emergencies]]></article-title>
<source><![CDATA[West J Emerg Med]]></source>
<year>2019</year>
<volume>20</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>316-22</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calvo-Villas]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome de lisis tumoral]]></article-title>
<source><![CDATA[Med Clin]]></source>
<year>2019</year>
<volume>152</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>397-04</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dubbs]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rapid fire: tumor lysis syndrome]]></article-title>
<source><![CDATA[Emerg Med Clin North Am]]></source>
<year>2018</year>
<volume>36</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>517-25</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davidson]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Thakkar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hix]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Bhandarkar]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schreiber]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathophysiology, clinical consequences and treatment of tumor lysis syndrome]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>2004</year>
<volume>116</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>546-54</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hochberg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cairo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumor lysis syndrome: current perspective]]></article-title>
<source><![CDATA[Haematologica]]></source>
<year>2008</year>
<volume>93</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>9-13</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soares]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Feres]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Salluh]]></surname>
<given-names><![CDATA[JIF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic inflammatory response syndrome and multiple organ dysfunction in patients with acute tumor lysis syndrome]]></article-title>
<source><![CDATA[Clinics (Sao Paulo)]]></source>
<year>2009</year>
<volume>64</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>479-81</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cairo]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Bishop]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumor lysis syndrome: new therapeutic strategies and classification]]></article-title>
<source><![CDATA[Br J Haematol]]></source>
<year>2004</year>
<volume>127</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3-11</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Howard]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Pui]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The tumor lysis syndrome]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2011</year>
<volume>364</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>1844-54</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McBride]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Trifilio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Baxter]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Gregory]]></surname>
<given-names><![CDATA[TK]]></given-names>
</name>
<name>
<surname><![CDATA[Howard]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Managing tumor lysis syndrome in the era of novel cancer therapies]]></article-title>
<source><![CDATA[J Adv Pract Oncol]]></source>
<year>2017</year>
<volume>8</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>705-20</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Darmon]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Guichard]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Vincent]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Schlemmer]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Azoulay]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic significance of acute renal injury in acute tumor lysis syndrome]]></article-title>
<source><![CDATA[Leuk Lymphoma]]></source>
<year>2010</year>
<volume>51</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>221-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vasseur]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Moreau]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analysis of the British guidelines 2015 for the management of adult tumor lysis syndrome]]></article-title>
<source><![CDATA[Reanimation]]></source>
<year>2017</year>
<volume>26</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>285-95</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dupré]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mousseaux]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bouguerba]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ayed]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Barchazs]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Boukari]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analysis of the 2015 British guidelines on the prevention and management of tumor lysis syndrome French]]></article-title>
<source><![CDATA[Rev Med Interne]]></source>
<year>2017</year>
<volume>38</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>36-43</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<collab>Comité Nacional de Hematología</collab>
<article-title xml:lang=""><![CDATA[Guideline for management of tumor lysis syndrome]]></article-title>
<source><![CDATA[Arch Argent Pediatr]]></source>
<year>2011</year>
<volume>109</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>77-82</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Will]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tholouli]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The clinical management of tumour lysis syndrome in haematological malignancies: review]]></article-title>
<source><![CDATA[Br J Haematol]]></source>
<year>2011</year>
<volume>154</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3-13</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lopez-Olivo]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Pratt]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Palla]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Salahudeen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rasburicase in tumor lysis syndrome of the adult: A systematic review and meta-analysis]]></article-title>
<source><![CDATA[Am J Kidney Dis]]></source>
<year>2013</year>
<volume>62</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>481-92</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cairo]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tangirala]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Eaddy]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A clinical and economic comparison of rasburicase and allopurinol in the treatment of patients with clinical or laboratory tumor lysis syndrome]]></article-title>
<source><![CDATA[Clin Lymphoma Myeloma Leuk]]></source>
<year>2017</year>
<volume>17</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>173-8</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mughal]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
<name>
<surname><![CDATA[Ejaz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Foringer]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Coiffier]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome]]></article-title>
<source><![CDATA[Cancer Treat Rev]]></source>
<year>2010</year>
<volume>36</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>164-76</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[FP]]></given-names>
</name>
<name>
<surname><![CDATA[Berns]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Onco-nephrology: tumor lysis syndrome]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2012</year>
<volume>7</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1730-9</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Durani]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
<name>
<surname><![CDATA[Go]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In-hospital outcomes of tumor lysis syndrome: a population based study using the national inpatient sample]]></article-title>
<source><![CDATA[Oncologist]]></source>
<year>2017</year>
<volume>22</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1506-9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
